{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:28:56Z","timestamp":1787048936022,"version":"build-2736575974"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04535-x","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:18:21Z","timestamp":1787041101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cWhat really works for us?\u201d exploring therapeutic strategies for non-small cell lung cancer: an umbrella review of systematic reviews and meta-analyses"],"prefix":"10.1007","author":[{"given":"Xinyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1960-8924","authenticated-orcid":false,"given":"Ruoyi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"4535_CR1","unstructured":"Bray FA-O, Laversanne M, Sung HA-O, Ferlay J, Siegel RA-O, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (1542-4863 (Electronic))."},{"issue":"1","key":"4535_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. Nature Reviews Disease Primers. 2024;10(1):71.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4535_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(1):39-51.","journal-title":"J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer"},{"issue":"9804","key":"4535_CR4","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","volume":"378","author":"P Goldstraw","year":"2011","unstructured":"Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet (London, England). 2011;378(9804):1727-40.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"4535_CR5","first-page":"459","volume":"21","author":"X Zhou","year":"2020","unstructured":"Zhou X, Zhang Z, Liang X. Regulatory Network Analysis to Reveal Important miRNAs and Genes in Non-Small Cell Lung Cancer. Cell journal. 2020;21(4):459-66.","journal-title":"Cell J"},{"issue":"10","key":"4535_CR6","volume":"2","author":"JM Lee","year":"2021","unstructured":"Lee JM, Kim AW, Marjanski T, Falcoz PE, Tsuboi M, Wu YL, et al. Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC. JTO clinical and research reports. 2021;2(10):100221.","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"4535_CR7","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.21037\/jtd-21-1007","volume":"13","author":"F Zhang","year":"2021","unstructured":"Zhang F, Qiu B, Ji Y, Guo W, Li N, Xue Q, et al. Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study. Journal of thoracic disease. 2021;13(10):5604-16.","journal-title":"J Thorac Dis"},{"issue":"5","key":"4535_CR8","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","volume":"165","author":"R Rajaram","year":"2024","unstructured":"Rajaram R, Huang Q, Li RZ, Chandran U, Zhang Y, Amos TB, et al. Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis. Chest. 2024;165(5):1260-70.","journal-title":"Chest"},{"issue":"10","key":"4535_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England journal of medicine. 2009;361(10):947-57.","journal-title":"N Engl J Med"},{"issue":"2","key":"4535_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. The New England journal of medicine. 2023;389(2):137-47.","journal-title":"N Engl J Med"},{"issue":"10","key":"4535_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O'Brien","year":"2022","unstructured":"O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. The Lancet Oncology. 2022;23(10):1274-86.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4535_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","volume":"39","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer cell. 2021;39(9):1279-91.e3.","journal-title":"Cancer Cell"},{"issue":"4","key":"4535_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(4):249-74.","journal-title":"J Natl Compr Canc Netw"},{"key":"4535_CR14","doi-asserted-by":"crossref","unstructured":"Tang S, Qin C, Hu H, Liu T, He Y, Guo H, et al. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells. 2022;11(3).","DOI":"10.3390\/cells11030320"},{"issue":"2","key":"4535_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1758834009338633","volume":"1","author":"JS Lind","year":"2009","unstructured":"Lind JS, Smit EF. Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Ther Adv Med Oncol. 2009;1(2):95-107.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"4535_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature reviews Cancer. 2005;5(5):341-54.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4535_CR17","first-page":"1997","volume":"19","author":"YJ Guo","year":"2020","unstructured":"Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK\/MAPK signalling pathway and tumorigenesis. Experimental and therapeutic medicine. 2020;19(3):1997-2007.","journal-title":"Exp Ther Med"},{"issue":"22","key":"4535_CR18","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1101\/gad.12.22.3499","volume":"12","author":"JA Diehl","year":"1998","unstructured":"Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes & development. 1998;12(22):3499-511.","journal-title":"Genes Dev"},{"issue":"24","key":"4535_CR19","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.1158\/1078-0432.CCR-06-0658","volume":"12","author":"GJ Riely","year":"2006","unstructured":"Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(24):7232-41.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"4535_CR20","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMe1205943","volume":"366","author":"A Ribas","year":"2012","unstructured":"Ribas A. Tumor immunotherapy directed at PD-1. The New England journal of medicine. 2012;366(26):2517-9.","journal-title":"N Engl J Med"},{"key":"4535_CR21","doi-asserted-by":"crossref","unstructured":"Rook AH, Raphael BA. Progress in immunotherapy of cancer. The New England journal of medicine. 2012;367(12):1168; author reply","DOI":"10.1056\/NEJMc1208946"},{"issue":"4","key":"4535_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","volume":"20","author":"C Viallard","year":"2017","unstructured":"Viallard C, Larriv\u00e9e B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409-26.","journal-title":"Angiogenesis"},{"issue":"6","key":"4535_CR23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248-64.","journal-title":"Cell"},{"issue":"12","key":"4535_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM. VEGF targets the tumour cell. Nature reviews Cancer. 2013;13(12):871-82.","journal-title":"Nat Rev Cancer"},{"key":"4535_CR25","doi-asserted-by":"crossref","unstructured":"Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, et al. Angiogenesis Inhibitors in NSCLC. International journal of molecular sciences. 2017;18(10).","DOI":"10.3390\/ijms18102021"},{"issue":"11","key":"4535_CR26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41(11):1999-2006.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"11","key":"4535_CR27","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G de Castro","year":"2023","unstructured":"de Castro G, Jr., Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41(11):1986-91.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"15_suppl","key":"4535_CR28","doi-asserted-by":"publisher","first-page":"e20560","DOI":"10.1200\/JCO.2019.37.15_suppl.e20560","volume":"37","author":"M Dyer","year":"2019","unstructured":"Dyer M, Green M, jones s, Hodge R. Estimating long-term survival of previously untreated patients with EGFR mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC) who received osimertinib in the FLAURA study. Journal of Clinical Oncology. 2019;37(15_suppl):e20560-e.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4535_CR29","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","volume":"31","author":"LG Paz-Ares","year":"2013","unstructured":"Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol J-L, Bidoli P, et al. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer. Journal of Clinical Oncology. 2013;31(23):2895-902.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4535_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1525-7304(11)70620-9","volume":"2","author":"MD Fisher","year":"2000","unstructured":"Fisher MD, D'Orazio A. Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clinical lung cancer. 2000;2(1):21-2.","journal-title":"Clin Lung Cancer"},{"issue":"Suppl 2","key":"4535_CR31","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.3816\/CLC.2002.s.010","volume":"3","author":"FV Fossella","year":"2002","unstructured":"Fossella FV. Docetaxel in second-line treatment of non-small-cell lung cancer. Clinical lung cancer. 2002;3 Suppl 2:S23-8.","journal-title":"Clin Lung Cancer"},{"issue":"9","key":"4535_CR32","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","volume":"26","author":"YL Wu","year":"2015","unstructured":"Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26(9):1883-9.","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"11","key":"4535_CR33","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2017;18(11):1454-66.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4535_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine. 2018;378(2):113-25.","journal-title":"N Engl J Med"},{"issue":"2","key":"4535_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","volume":"161","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Fu F, Hu H, Wang S, Li Y, Hu H, et al. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study. The Journal of thoracic and cardiovascular surgery. 2021;161(2):434-42.e2.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"22","key":"4535_CR36","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","volume":"36","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(22):2251-8.","journal-title":"J Clin Oncol"},{"key":"4535_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","volume":"151","author":"N Yamamoto","year":"2021","unstructured":"Yamamoto N, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung cancer (Amsterdam, Netherlands). 2021;151:20-4.","journal-title":"Lung Cancer"},{"issue":"19","key":"4535_CR38","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"1823","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2016;375(19):1823-33.","journal-title":"N Engl J Med"},{"issue":"4","key":"4535_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","volume":"16","author":"M Nishio","year":"2021","unstructured":"Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021;16(4):653-64.","journal-title":"J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer"},{"issue":"3","key":"4535_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","volume":"70","author":"J Qu","year":"2021","unstructured":"Qu J, Mei Q, Chen L, Zhou J. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer immunology, immunotherapy : CII. 2021;70(3):619-31.","journal-title":"Cancer Immunol, Immunother : CII"},{"issue":"10454","key":"4535_CR41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet (London, England). 2024;404(10454):803-22.","journal-title":"Lancet (London, England)"},{"issue":"21","key":"4535_CR42","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.23.00013","volume":"41","author":"A Passaro","year":"2023","unstructured":"Passaro A, J\u00e4nne PA, Peters S. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41(21):3747-61.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"8","key":"4535_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/COC.0000000000000706","volume":"43","author":"ST Chao","year":"2020","unstructured":"Chao ST, Dad LK, Dawson LA, Desai NB, Pacella M, Rengan R, et al. ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy. American journal of clinical oncology. 2020;43(8):545-52.","journal-title":"Am J Clin Oncol"},{"issue":"Suppl 6","key":"4535_CR44","doi-asserted-by":"publisher","first-page":"S517","DOI":"10.21037\/jtd.2016.03.14","volume":"8","author":"MW Tsang","year":"2016","unstructured":"Tsang MW. Stereotactic body radiotherapy: current strategies and future development. Journal of thoracic disease. 2016;8(Suppl 6):S517-27.","journal-title":"J Thorac Dis"},{"issue":"10422","key":"4535_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet (London, England). 2024;403(10422):171-82.","journal-title":"Lancet (London, England)"},{"issue":"12","key":"4535_CR46","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S2213-2600(24)00215-7","volume":"12","author":"ZR Zhao","year":"2024","unstructured":"Zhao ZR, Liu SL, Zhou T, Chen G, Long H, Su XD, et al. Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial. The Lancet Respiratory medicine. 2024;12(12):988-96.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"4535_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1109\/MPUL.2011.942603","volume":"2","author":"C Brace","year":"2011","unstructured":"Brace C. Thermal tumor ablation in clinical use. IEEE pulse. 2011;2(5):28-38.","journal-title":"IEEE pulse"},{"issue":"10","key":"4535_CR48","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.1634\/theoncologist.2018-0337","volume":"24","author":"F Izzo","year":"2019","unstructured":"Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, et al. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. The oncologist. 2019;24(10):e990-e1005.","journal-title":"Oncologist"},{"key":"4535_CR49","doi-asserted-by":"publisher","first-page":"1240149","DOI":"10.3389\/fimmu.2023.1240149","volume":"14","author":"Z Yang","year":"2023","unstructured":"Yang Z, Lyu X, Yang H, Wang B, Xu D, Huo L, et al. Survival after radiofrequency ablation and\/or chemotherapy for lung cancer and pulmonary metastases: a systematic review and meta-analysis. Frontiers in immunology. 2023;14:1240149.","journal-title":"Front Immunol"},{"key":"4535_CR50","doi-asserted-by":"publisher","first-page":"111381","DOI":"10.1016\/j.biopha.2021.111381","volume":"137","author":"Z Li","year":"2021","unstructured":"Li Z, Feiyue Z, Gaofeng L. Traditional Chinese medicine and lung cancer--From theory to practice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021;137:111381.","journal-title":"Biomed Pharmacother = Biomed pharmacother"},{"key":"4535_CR51","doi-asserted-by":"publisher","first-page":"4369027","DOI":"10.1155\/2018\/4369027","volume":"2018","author":"X Zhao","year":"2018","unstructured":"Zhao X, Dai X, Wang S, Yang T, Yan Y, Zhu G, et al. Traditional Chinese Medicine Integrated with Chemotherapy for Stage II-IIIA Patients with Non-Small-Cell Lung Cancer after Radical Surgery: A Retrospective Clinical Analysis with Small Sample Size. Evidence-based complementary and alternative medicine : eCAM. 2018;2018:4369027.","journal-title":"Evidence-based Complement Altern Med : eCAM"},{"issue":"4","key":"4535_CR52","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","volume":"31","author":"GR Oxnard","year":"2020","unstructured":"Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020;31(4):507-16.","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"11","key":"4535_CR53","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.jtho.2023.09.043","volume":"18","author":"KP Papadopoulos","year":"2023","unstructured":"Papadopoulos KP, Bruno D, Kitazono S, Murakami S, Gutierrez M, Wakuda K, et al. OA05.06 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab \u00b1 Carboplatin in Advanced\/mNSCLC: Initial Results from Phase 1b TROPION-Lung04. Journal of Thoracic Oncology. 2023;18(11):S55.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4535_CR54","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. Journal of hematology & oncology. 2021;14(1):156.","journal-title":"J Hematol Oncol"},{"key":"4535_CR55","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034366.","journal-title":"SAGE Open Med"},{"issue":"Pt B","key":"4535_CR56","doi-asserted-by":"publisher","first-page":"110919","DOI":"10.1016\/j.intimp.2023.110919","volume":"124","author":"J Chen","year":"2023","unstructured":"Chen J, Chen S, Luo H, Long S, Yang X, He W, et al. The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review. Int Immunopharmacol. 2023;124(Pt B):110919.","journal-title":"Int Immunopharmacol"},{"key":"4535_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107007","volume":"198","author":"J Chen","year":"2023","unstructured":"Chen J, Chen S, Luo H, Wan X, Wu W, Wang S. The complementary and alternative roles of elemene injection in cancer: An umbrella review. Pharmacol Res. 2023;198:107007.","journal-title":"Pharmacol Res"},{"key":"4535_CR58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","volume":"69","author":"P Whiting","year":"2016","unstructured":"Whiting P, Savovi\u0107 J, Higgins JP, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. Journal of clinical epidemiology. 2016;69:225-34.","journal-title":"J Clin Epidemiol"},{"key":"4535_CR59","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj. 2017;358:j4008.","journal-title":"Bmj"},{"issue":"7650","key":"4535_CR60","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924-6.","journal-title":"BMJ"},{"issue":"3","key":"4535_CR61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","volume":"13","author":"E Aromataris","year":"2015","unstructured":"Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. International journal of evidence-based healthcare. 2015;13(3):132-40.","journal-title":"Int J Evid Based Healthc"},{"issue":"4","key":"4535_CR62","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","volume":"67","author":"D Pieper","year":"2014","unstructured":"Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. Journal of clinical epidemiology. 2014;67(4):368-75.","journal-title":"J Clin Epidemiol"},{"key":"4535_CR63","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. Bmj. 2011;342:d549.","journal-title":"Bmj"},{"issue":"2","key":"4535_CR64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Research synthesis methods. 2010;1(2):97-111.","journal-title":"Res Synth Methods"},{"issue":"3","key":"4535_CR65","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/jrsm.1301","volume":"9","author":"C Watkins","year":"2018","unstructured":"Watkins C, Bennett I. A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data. Research synthesis methods. 2018;9(3):352-60.","journal-title":"Res Synth Methods"},{"issue":"5","key":"4535_CR66","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/jrsm.1658","volume":"14","author":"M Kirvalidze","year":"2023","unstructured":"Kirvalidze M, Abbadi A, Dahlberg L, Sacco LB, Calder\u00f3n-Larra\u00f1aga A, Morin L. Estimating pairwise overlap in umbrella reviews: Considerations for using the corrected covered area (CCA) index methodology. Research synthesis methods. 2023;14(5):764-7.","journal-title":"Res Synth Methods"},{"issue":"8","key":"4535_CR67","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10654-020-00712-6","volume":"36","author":"VS Biller","year":"2021","unstructured":"Biller VS, Leitzmann MF, Sedlmeier AM, Berger FF, Ortmann O, Jochem C. Sedentary behaviour in relation to ovarian cancer risk: a systematic review and meta-analysis. European journal of epidemiology. 2021;36(8):769-80.","journal-title":"Eur J Epidemiol"},{"key":"4535_CR68","doi-asserted-by":"publisher","first-page":"e077310","DOI":"10.1136\/bmj-2023-077310","volume":"384","author":"MM Lane","year":"2024","unstructured":"Lane MM, Gamage E, Du S, Ashtree DN, McGuinness AJ, Gauci S, et al. Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses. Bmj. 2024;384:e077310.","journal-title":"Bmj"},{"issue":"1","key":"4535_CR69","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","volume":"18","author":"MA Cupp","year":"2020","unstructured":"Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC medicine. 2020;18(1):360.","journal-title":"BMC medicine"},{"key":"4535_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915207","volume":"13","author":"Z Hu","year":"2022","unstructured":"Hu Z, Zhou J, Li Y, Luan Y, Li H, Jia B, et al. Peripheral immune signature resembles tumor microenvironment and predicts clinical outcomes in head and neck squamous cell carcinoma. Frontiers in immunology. 2022;13:915207.","journal-title":"Front Immunol"},{"issue":"7644","key":"4535_CR71","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","volume":"336","author":"L Wood","year":"2008","unstructured":"Wood L, Egger M, Gluud LL, Schulz KF, J\u00fcni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. Bmj. 2008;336(7644):601-5.","journal-title":"BMJ"},{"issue":"8","key":"4535_CR72","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S1470-2045(13)70254-7","volume":"14","author":"YL Wu","year":"2013","unstructured":"Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. The Lancet Oncology. 2013;14(8):777-86.","journal-title":"Lancet Oncol"},{"issue":"15","key":"4535_CR73","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1200\/JCO.2020.38.15_suppl.9506","volume":"38","author":"M Maemondo","year":"2020","unstructured":"Maemondo M, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. Journal of Clinical Oncology.38(15_suppl):9506-.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4535_CR74","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England journal of medicine. 2014;371(23):2167-77.","journal-title":"N Engl J Med"},{"issue":"9","key":"4535_CR75","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017;377(9):829-38.","journal-title":"N Engl J Med"},{"key":"4535_CR76","doi-asserted-by":"crossref","unstructured":"Lee YC, Hsieh CC, Lee YL, Li CY. Which Should Be Used First for ALK-Positive Non-Small-Cell Lung Cancer: Chemotherapy or Targeted Therapy? A Meta-Analysis of Five Randomized Trials. Medicina (Kaunas, Lithuania). 2019;55(2).","DOI":"10.3390\/medicina55020029"},{"key":"4535_CR77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.lungcan.2021.11.008","volume":"162","author":"K Matsumoto","year":"2021","unstructured":"Matsumoto K, Shiroyama T, Kuge T, Miyake K, Yamamoto Y, Yoneda M, et al. Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2021;162:175-84.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"22","key":"4535_CR78","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2078","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England journal of medicine. 2018;378(22):2078-92.","journal-title":"N Engl J Med"},{"issue":"26","key":"4535_CR79","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2015.66.3955","volume":"34","author":"F Dammeijer","year":"2016","unstructured":"Dammeijer F, Lievense LA, Veerman GD, Hoogsteden HC, Hegmans JP, Arends LR, et al. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(26):3204-12.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4535_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108958","volume":"9","author":"RX Han","year":"2014","unstructured":"Han RX, Liu X, Pan P, Jia YJ, Yu JC. Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis. PloS one. 2014;9(9):e108958.","journal-title":"PLoS ONE"},{"key":"4535_CR81","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.intimp.2018.06.012","volume":"61","author":"Z Xiao","year":"2018","unstructured":"Xiao Z, Wang CQ, Zhou MH, Li NN, Liu SY, He YJ, et al. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials. Int Immunopharmacol. 2018;61:363-75.","journal-title":"Int Immunopharmacol"},{"issue":"14","key":"4535_CR82","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMp1711886","volume":"377","author":"L Rosenbaum","year":"2017","unstructured":"Rosenbaum L. Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy. The New England journal of medicine. 2017;377(14):1313-5.","journal-title":"N Engl J Med"},{"issue":"7","key":"4535_CR83","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nature reviews Clinical oncology. 2024;21(7):501-21.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"4535_CR84","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s11864-022-01002-x","volume":"23","author":"L Faroni","year":"2022","unstructured":"Faroni L, Collie L, Gabrielli F, Baldotto C, Moraes F. Role of Stereotactic Radiation Therapy in Operable and Inoperable Early-Stage Non-small Cell Lung Cancer. Current treatment options in oncology. 2022;23(9):1185-200.","journal-title":"Curr Treat Options Oncol"},{"issue":"17","key":"4535_CR85","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jnci\/88.17.1210","volume":"88","author":"RO Dillman","year":"1996","unstructured":"Dillman RO, Herndon J, Seagren SL, Eaton WL, Jr., Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. Journal of the National Cancer Institute. 1996;88(17):1210-5.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4535_CR86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-025-02245-6","volume":"24","author":"Z Xi","year":"2025","unstructured":"Xi Z, Dai R, Ze Y, Jiang X, Liu M, Xu H. Traditional Chinese medicine in lung cancer treatment. Molecular cancer. 2025;24(1):57.","journal-title":"Molecular cancer"},{"issue":"1","key":"4535_CR87","doi-asserted-by":"publisher","first-page":"e087181","DOI":"10.1136\/bmjopen-2024-087181","volume":"15","author":"X Wan","year":"2025","unstructured":"Wan X, Mo H, Chen J, Zhou Q, Qiu S, Zou Y, et al. Risk factors for brain metastasis in lung cancer: an umbrella review of systematic reviews and meta-analyses. BMJ open. 2025;15(1):e087181.","journal-title":"BMJ open"},{"issue":"1","key":"4535_CR88","doi-asserted-by":"publisher","first-page":"3","DOI":"10.12997\/jla.2023.12.1.3","volume":"12","author":"GJ Choi","year":"2023","unstructured":"Choi GJ, Kang H. Introduction to Umbrella Reviews as a Useful Evidence-Based Practice. J Lipid Atheroscler. 2023;12(1):3-11.","journal-title":"J Lipid Atheroscler"},{"key":"4535_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2015.12.008","volume":"23","author":"V Bellou","year":"2016","unstructured":"Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP. Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism & related disorders. 2016;23:1-9.","journal-title":"Parkinsonism Relat Disord"},{"key":"4535_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102572","volume":"118","author":"C Parisi","year":"2023","unstructured":"Parisi C, Mahjoubi L, Gazzah A, Barlesi F. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer treatment reviews. 2023;118:102572.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"4535_CR91","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/cpdd.427","volume":"7","author":"E-H Tan","year":"2018","unstructured":"Tan E-H, Lim W-T, Ahn M-J, Ng Q-S, Ahn JS, Shao-Weng Tan D, et al. Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Clinical Pharmacology in Drug Development. 2018;7(5):532-42.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4535_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/srep15355","volume":"5","author":"H Yan","year":"2015","unstructured":"Yan H, Li Q, Wang W, Zhen H, Cao B. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients. Sci Rep. 2015;5:15355.","journal-title":"Sci Rep"},{"issue":"11","key":"4535_CR93","first-page":"cd009948","volume":"2014","author":"ZY Yang","year":"2014","unstructured":"Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, et al. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. The Cochrane database of systematic reviews. 2014;2014(11):Cd009948.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"4535_CR94","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1177\/1078155219891631","volume":"26","author":"I Ilic","year":"2020","unstructured":"Ilic I, Sipetic S, Grujicic J, Ilic M. Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020;26(6):1331-42.","journal-title":"J Oncol Pharm Pract : Off Publ Int Soc Oncol Pharm Pract"},{"key":"4535_CR95","doi-asserted-by":"publisher","first-page":"5537899","DOI":"10.1155\/2021\/5537899","volume":"2021","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, He M, Li R, Peng Y, Li F, Li S, et al. The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. BioMed research international. 2021;2021:5537899.","journal-title":"Biomed Res Int"},{"issue":"12","key":"4535_CR96","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jamaoncol.2016.2050","volume":"2","author":"FN Santos","year":"2016","unstructured":"Santos FN, Cruz MR, Riera R. Chemotherapy for Advanced Non-Small-Cell Lung Cancer in Elderly Patients. JAMA oncology. 2016;2(12):1645-6.","journal-title":"JAMA Oncol"},{"issue":"5","key":"4535_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037229","volume":"7","author":"M Li","year":"2012","unstructured":"Li M, Zhang Q, Fu P, Li P, Peng A, Zhang G, et al. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PloS one. 2012;7(5):e37229.","journal-title":"PLoS ONE"},{"issue":"10","key":"4535_CR98","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/JTO.0b013e318153fa2b","volume":"2","author":"JY Douillard","year":"2007","unstructured":"Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(10):939-46.","journal-title":"J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer"},{"issue":"1","key":"4535_CR99","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.lungcan.2004.10.014","volume":"47","author":"T Le Chevalier","year":"2005","unstructured":"Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung cancer (Amsterdam, Netherlands). 2005;47(1):69-80.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"4535_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105747","volume":"75","author":"FL Zeng","year":"2019","unstructured":"Zeng FL, Xiao Z, Wang CQ, Jiang Y, Shan JL, Hu SS, et al. Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. Int Immunopharmacol. 2019;75:105747.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"4535_CR101","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00262-021-03031-1","volume":"71","author":"T Landre","year":"2022","unstructured":"Landre T, Justeau G, Assi\u00e9 JB, Chouahnia K, Davoine C, Taleb C, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer immunology, immunotherapy : CII. 2022;71(3):719-26.","journal-title":"Cancer Immunol, Immunother : CII"},{"issue":"4","key":"4535_CR102","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/1759-7714.12971","volume":"10","author":"R Chen","year":"2019","unstructured":"Chen R, Hou X, Yang L, Zhao D. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis. Thoracic cancer. 2019;10(4):607-23.","journal-title":"Thorac Cancer"},{"key":"4535_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107594","volume":"96","author":"DC Mo","year":"2021","unstructured":"Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. Int Immunopharmacol. 2021;96:107594.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4535_CR104","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s40425-018-0477-9","volume":"6","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, et al. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. Journal for immunotherapy of cancer. 2018;6(1):155.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4535_CR105","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1002\/jcp.29371","volume":"235","author":"C Wang","year":"2020","unstructured":"Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Wang T, et al. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. Journal of cellular physiology. 2020;235(5):4913-27.","journal-title":"J Cell Physiol"},{"issue":"2","key":"4535_CR106","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017;12(2):403-7.","journal-title":"J Thorac Oncol : Off Pub Int Assoc Study Lung Cancer"},{"key":"4535_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666909","volume":"12","author":"DN Li","year":"2021","unstructured":"Li DN, Lu WQ, Yang BW, Zhang LY, Jin B, Wang S, et al. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis. Frontiers in immunology. 2021;12:666909.","journal-title":"Front Immunol"},{"issue":"2","key":"4535_CR108","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.lungcan.2014.02.016","volume":"84","author":"SH Patel","year":"2014","unstructured":"Patel SH, Ma Y, Wernicke AG, Nori D, Chao KS, Parashar B. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. Lung cancer (Amsterdam, Netherlands). 2014;84(2):156-60.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"2","key":"4535_CR109","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.brachy.2017.11.015","volume":"17","author":"W Zhang","year":"2018","unstructured":"Zhang W, Li J, Li R, Zhang Y, Han M, Ma W. Efficacy and safety of iodine-125 radioactive seeds brachytherapy for advanced non-small cell lung cancer-A meta-analysis. Brachytherapy. 2018;17(2):439-48.","journal-title":"Brachytherapy"},{"issue":"27","key":"4535_CR110","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016167","volume":"98","author":"MS Hung","year":"2019","unstructured":"Hung MS, Wu YF, Chen YC. Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: A meta-analysis and systematic review. Medicine. 2019;98(27):e16167.","journal-title":"Medicine"},{"issue":"28","key":"4535_CR111","doi-asserted-by":"publisher","first-page":"e29580","DOI":"10.1097\/MD.0000000000029580","volume":"101","author":"D Li","year":"2022","unstructured":"Li D, Li W, Pang Y, Xu L, Xu X. The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis. Medicine. 2022;101(28):e29580.","journal-title":"Medicine"},{"key":"4535_CR112","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jep.2018.04.013","volume":"221","author":"J Wang","year":"2018","unstructured":"Wang J, Li G, Yu L, Mo T, Wu Q, Zhou Z. Aidi injection plus platinum-based chemotherapy for stage IIIB\/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines. Journal of ethnopharmacology. 2018;221:137-50.","journal-title":"J Ethnopharmacol"},{"issue":"35","key":"4535_CR113","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016969","volume":"98","author":"F Zhang","year":"2019","unstructured":"Zhang F, Yin Y, Xu T. Cinobufotalin injection combined with chemotherapy for the treatment of advanced NSCLC in China: A PRISMA-compliant meta-analysis of 29 randomized controlled trials. Medicine. 2019;98(35):e16969.","journal-title":"Medicine"},{"issue":"3","key":"4535_CR114","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2005.03.6392","volume":"24","author":"M McCulloch","year":"2006","unstructured":"McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(3):419-30.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"31","key":"4535_CR115","doi-asserted-by":"publisher","first-page":"e21490","DOI":"10.1097\/MD.0000000000021490","volume":"99","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Sun K, Lei X, Cai L. A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer. Medicine. 2020;99(31):e21490.","journal-title":"Medicine"},{"key":"4535_CR116","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lungcan.2016.10.004","volume":"102","author":"BT Li","year":"2016","unstructured":"Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, et al. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung cancer (Amsterdam, Netherlands). 2016;102:21-7.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"4","key":"4535_CR117","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cllc.2017.01.004","volume":"18","author":"J Raphael","year":"2017","unstructured":"Raphael J, Chan K, Karim S, Kerbel R, Lam H, Santos KD, et al. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials. Clinical lung cancer. 2017;18(4):345-53.e5.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"4535_CR118","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/j.cllc.2020.08.005","volume":"22","author":"Z Deng","year":"2021","unstructured":"Deng Z, Qin Y, Liu Y, Zhang Y, Lu Y. Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis. Clinical lung cancer. 2021;22(1):e70-e83.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"4535_CR119","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/1759-7714.13867","volume":"12","author":"ABC Brito","year":"2021","unstructured":"Brito ABC, Camandaroba MPG, de Lima VCC. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. Thoracic cancer. 2021;12(7):1058-66.","journal-title":"Thoracic cancer"},{"issue":"3","key":"4535_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032695","volume":"7","author":"J Wang","year":"2012","unstructured":"Wang J, Zou ZH, Xia HL, He JX, Zhong NS, Tao AL. Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PloS one. 2012;7(3):e32695.","journal-title":"PLoS ONE"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04535-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04535-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04535-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:01:59Z","timestamp":1787047319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04535-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":120,"alternative-id":["4535"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04535-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}